Hospital Mater Dei (MATD3) investor relations material

Executive summary

• Achieved record consolidated net revenue of BRL 614 million in Q2 2026, up 12.4% year-over-year, driven by higher average ticket, patient volume, and strategic planning.

• Adjusted EBITDA grew 20.3% YoY to BRL 139 million, with margin rising to 22.6%, and net income increased 66.1% YoY to BRL 45 million.

• Operational efficiency, expansion of robotic surgery and AI tools, and improved specialty mix supported record results.

• Strong ramp-up in newer units, notably Salvador (+30% revenue YoY, 133% oncology patient growth) and Nova Lima (+84% net revenue YoY, 25% oncology patient growth).

• Strategic partnerships and new accreditations, such as Bradesco Saúde Efetivo Plus in Bahia, expanded regional presence and market consolidation.

Financial highlights

• Net revenue reached BRL 614 million, a 12.4% increase YoY and 6.7% sequentially; gross profit was BRL 186.7 million (+13.3% YoY), with gross margin at 30.4%.

• Adjusted EBITDA was BRL 139 million, up 20.3% YoY, with margin at 22.6%; net profit rose 66.1% YoY to BRL 45 million, margin up 2.3pp to 7.3%.

• ROIC improved by 50% since 2024, reaching 10.8% annualized.

• Net debt/EBITDA reduced to 1.5x, with net debt down by BRL 37 million to BRL 763 million; weighted average debt maturity at 4.98 years.

• Cash flow to shareholders totaled BRL 238 million, with BRL 74 million in dividends and BRL 110 million in share buybacks.

Outlook and guidance

• Optimism for continued volume and revenue growth in Q3 and H2 2026, supported by new teams, partnerships, and expansion in Bahia.

• Ongoing focus on operational efficiency, specialty mix, cost control, and strategic capital allocation.